Literature DB >> 16606358

Direct interaction of post-synaptic density-95/Dlg/ZO-1 domain-containing synaptic molecule Shank3 with GluR1 alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor.

Shigeo Uchino1, Hidenori Wada, Shizuyo Honda, Yasuko Nakamura, Yumiko Ondo, Takayoshi Uchiyama, Moe Tsutsumi, Eri Suzuki, Takae Hirasawa, Shinichi Kohsaka.   

Abstract

A class of scaffolding protein containing the post-synaptic density-95/Dlg/ZO-1 (PDZ) domain is thought to be involved in synaptic trafficking of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors during development. To clarify the molecular mechanism of AMPA receptor trafficking, we performed a yeast two-hybrid screening system using the cytoplasmic tail of the GluR1 subunit of AMPA receptor as a bait and identified a synaptic molecule, Shank3/ProSAP2, as a GluR1 subunit-interacting molecule. Shank3 is a PDZ domain-containing multidomain protein and is predominantly expressed in developing neurons. Using the glutathione S-transferase pull-down assay and immunoprecipitation technique we demonstrated that the GluR1 subunit directly binds to the PDZ domain of Shank3 via its carboxyl terminal PDZ-binding motif. We raised anti-Shank3 antibody to investigate the expression of Shank3 in cortical neurons. The pattern of Shank3 immunoreactivity was strikingly punctate, mainly observed in the spines, and closely matched the pattern of post-synaptic density-95 immunoreactivity, indicating that Shank3 is colocalized with post-synaptic density-95 in the same spines. When Shank3 and the GluR1 subunit were overexpressed in primary cortical neurons, they were also colocalized in the spines. Taken together with the biochemical interaction of Shank3 with the GluR1 subunit, these results suggest that Shank3 is an important molecule that interacts with GluR1 AMPA receptor at synaptic sites of developing neurons.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16606358     DOI: 10.1111/j.1471-4159.2006.03831.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  40 in total

Review 1.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

2.  Shank3-Rich2 interaction regulates AMPA receptor recycling and synaptic long-term potentiation.

Authors:  Fabrice Raynaud; Andrea Janossy; Janine Dahl; Federica Bertaso; Julie Perroy; Annie Varrault; Michel Vidal; Paul F Worley; Tobias M Boeckers; Joël Bockaert; Philippe Marin; Laurent Fagni; Vincent Homburger
Journal:  J Neurosci       Date:  2013-06-05       Impact factor: 6.167

3.  Loss of predominant Shank3 isoforms results in hippocampus-dependent impairments in behavior and synaptic transmission.

Authors:  Mehreen Kouser; Haley E Speed; Colleen M Dewey; Jeremy M Reimers; Allie J Widman; Natasha Gupta; Shunan Liu; Thomas C Jaramillo; Muhammad Bangash; Bo Xiao; Paul F Worley; Craig M Powell
Journal:  J Neurosci       Date:  2013-11-20       Impact factor: 6.167

4.  Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability.

Authors:  Fadi F Hamdan; Julie Gauthier; Yoichi Araki; Da-Ting Lin; Yuhki Yoshizawa; Kyohei Higashi; A-Reum Park; Dan Spiegelman; Sylvia Dobrzeniecka; Amélie Piton; Hideyuki Tomitori; Hussein Daoud; Christine Massicotte; Edouard Henrion; Ousmane Diallo; Masoud Shekarabi; Claude Marineau; Michael Shevell; Bruno Maranda; Grant Mitchell; Amélie Nadeau; Guy D'Anjou; Michel Vanasse; Myriam Srour; Ronald G Lafrenière; Pierre Drapeau; Jean Claude Lacaille; Eunjoon Kim; Jae-Ran Lee; Kazuei Igarashi; Richard L Huganir; Guy A Rouleau; Jacques L Michaud
Journal:  Am J Hum Genet       Date:  2011-03-03       Impact factor: 11.025

5.  Autism-associated SHANK3 missense point mutations impact conformational fluctuations and protein turnover at synapses.

Authors:  Michael Bucher; Stephan Niebling; Yuhao Han; Dmitry Molodenskiy; Fatemeh Hassani Nia; Hans-Jürgen Kreienkamp; Dmitri Svergun; Eunjoon Kim; Alla S Kostyukova; Michael R Kreutz; Marina Mikhaylova
Journal:  Elife       Date:  2021-05-04       Impact factor: 8.140

6.  Sensitivity to isoflurane anesthesia increases in autism spectrum disorder Shank3+/∆c mutant mouse model.

Authors:  Changsheng Li; Michele Schaefer; Christy Gray; Ya Yang; Orion Furmanski; Sufang Liu; Paul Worley; C David Mintz; Feng Tao; Roger A Johns
Journal:  Neurotoxicol Teratol       Date:  2016-11-14       Impact factor: 3.763

Review 7.  Phelan-McDermid Syndrome and SHANK3: Implications for Treatment.

Authors:  Jesse L Costales; Alexander Kolevzon
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

Review 8.  Modeling autism by SHANK gene mutations in mice.

Authors:  Yong-Hui Jiang; Michael D Ehlers
Journal:  Neuron       Date:  2013-04-10       Impact factor: 17.173

9.  A general screening strategy for peptide-based fluorogenic ligands: probes for dynamic studies of PDZ domain-mediated interactions.

Authors:  Matthieu Sainlos; Wendy S Iskenderian; Barbara Imperiali
Journal:  J Am Chem Soc       Date:  2009-05-20       Impact factor: 15.419

10.  Analysis of the potential role of GluA4 carboxyl-terminus in PDZ interactions.

Authors:  Sarah K Coleman; Chunlin Cai; Nisse Kalkkinen; Esa R Korpi; Kari Keinänen
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.